SAS Output

14-DEC-2018 6:10

BREAST ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9400 9383 0 0 0 0 0 02/28/2011 397 187
            9383 0 0 0 0 0      
 
    2 Y 2 Chemo and Endocrine Therapy 5000 2547 0 0 0 0 0 02/28/2011    
        3 Endocrine Therapy Alone   2536 0 0 0 0 0      
            5083 0 0 0 0 0      
 
  S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 1900 896 182 88 49 19 6 09/12/2013 443 207
        2 Blinded drug + Endocrine   901 177 84 42 16 4      
            1797 359 172 91 35 10      
 
  S1222-Brst,Fulv. +/- Ever. +/- Anastr. 1 T 1 Blinded treatment 840 12 0 0 0 0 0 05/15/2014 13 3
        2 Blinded treatment   12 0 0 0 0 0      
        3 Blinded treatment   13 0 0 0 0 0      
            37 0 0 0 0 0      
 
  S1416-Brst, TNBC/BRCA, Cis+/- ABT-888 1 Y 1 Blinded Drug + Cisplatin 333 138 43 15 12 3 1 09/15/2016 276 131
        2 Blinded Drug + Cisplatin   142 48 21 14 3 2      
            280 91 36 26 6 3      
 
  S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 1000 387 265 147 82 31 13 01/18/2017 478 211
            387 265 147 82 31 13      
 
    2 Y 2 Observation 1000 159 103 54 26 10 2 01/18/2017    
        3 MK-3475 (Pembrolizumab)   160 113 58 29 13 0      
            319 216 112 55 23 2      
 
Yes A011106-Breast, Neoadj, ALTERNATE study 1 E Total Registrations   80 29 21 6 0 0 04/29/2014   120
            80 29 21 6 0 0      
 
  E1Z11-Brst,Genetic Predictors of AIMSS 1 E Total Registrations   156 10 6 2 0 0 08/13/2013   23
            156 10 6 2 0 0      
 
  NRGBR003-Brst,Adj,TNBC,AC -> WP +/- Carbo 1 E Total Registrations   67 19 11 5 1 0 10/16/2015   173
            67 19 11 5 1 0      
 
  NRGBR005-Br, Stg II&IIIA, Post NAdj Chemo Br Conserv 1 E Total Registrations   6 6 6 4 2 0 06/22/2018 31 19
            6 6 6 4 2 0      
 
No A011401-Breast, adj, Stage II/III HER2-, weight loss 1 E Total Registrations   195 103 49 18 4 0 10/05/2016   244
            195 103 49 18 4 0      
 
    2 E Total Registrations   179 99 49 20 4 0 10/05/2016    
            179 99 49 20 4 0      
 
  A011502-Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo 1 E Total Registrations   65 43 19 13 5 1 03/20/2017 457 226
            65 43 19 13 5 1      
 
  A221405-Breast, ET interruption, Pregnancy Outcomes 1 E Total Registrations   13 5 4 1 0 0 05/08/2017 131 54
            13 5 4 1 0 0      
 
  B51-Breast, Regional Nodal XRT 1 E Total Registrations   33 10 7 2 1 0 06/13/2014   204
            33 10 7 2 1 0      
 
  B55-Brst, Adj Olaparib for BRCA,TNBC 1 E Total Registrations   68 19 9 2 0 0 12/15/2014 441 186
            68 19 9 2 0 0      
 
    2 E Total Registrations   32 11 6 0 0 0 12/15/2014    
            32 11 6 0 0 0      
 
  E2112-Brst,Adv,Exemestane+/-Entinostat 1 E Total Registrations   61 17 10 4 0 0 04/01/2015   175
            61 17 10 4 0 0      
 
  EA1131-Brst, TNBC, Post-op Chemo vs Obs 0 E Total Registrations   23 8 5 5 1 0 11/12/2015   133
            23 8 5 5 1 0      
 
    1 P Total Registrations   12 5 1 1 1 1 11/12/2015    
            12 5 1 1 1 1      
 
  EA1151-Brst, Tomosynthesis Mammographic Screening 1 E Total Registrations   256 256 148 78 25 6 01/30/2018 159 76
            256 256 148 78 25 6      
 
  NRGBR002-Brst, OMBC, II-III, SoC +/- SBRT and/or SA 1 E Total Registrations   1 0 0 0 0 0 09/22/2017 319 136
            1 0 0 0 0 0      
 

14-DEC-2018 6:10

BREAST Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1706 Breast, Inflammatory, RT +/- Olaparib 1 Randomization 12-Sep-18